M&A Deal Summary

EUSA Pharma Acquires SYLVANT

On July 18, 2018, EUSA Pharma acquired life science company SYLVANT from Janssen Biotech for 115M USD

Acquisition Highlights
  • This is EUSA Pharma’s 2nd transaction in the Life Science sector.
  • This is EUSA Pharma’s largest (disclosed) transaction.
  • This is EUSA Pharma’s 2nd transaction in the United States.

M&A Deal Summary
Date 2018-07-18
Target SYLVANT
Sector Life Science
Buyer(s) EUSA Pharma
Sellers(s) Janssen Biotech
Deal Type Divestiture
Deal Value 115M USD

Target

SYLVANT

United States
website
SYLVANT is approved in more than 40 countries worldwide, including the United States, the European Union, the Republic of Korea and Canada, for the treatment of idiopathic multicentric Castleman’s disease (iMCD), a rare, life threatening and debilitating orphan condition. Idiopathic MCD is an inflammatory lymphoproliferative disorder, which causes the abnormal overgrowth of immune cells and shares many symptomatic and histological features with lymphoma.1 The disease can affect individuals at any age, with iMCD representing one-third to half of all multicentric Castleman’s disease (MCD).

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

EUSA Pharma

Langhorne, Pennsylvania, United States

website

Category Company
Founded 2006
Sector Life Science
DESCRIPTION

EUSA Pharma is a trans-Atlantic specialty pharmaceutical company focused on oncology and critical care. EUSA intends to build a portfolio of products that are on the market or in late-stage clinical trials through acquisitions and in-licensing. The company has a sales and marketing organization and commercial infrastructure in the US and all major European countries.

DEAL STATS #
Overall 2 of 2
Sector (Life Science) 2 of 2
Type (Divestiture) 2 of 2
Country (United States) 2 of 2
Year (2018) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-10-04 Apeiron Biologics AG - Isqette

Langhorne, Pennsylvania, United States

Apeiron Biologics AG - Isqette (Dinutuximab Beta) is an immunotherapy has orphan drug designation in the US and EU and is currently under review for marketing authorization by the EMA.

Buy -

Seller(S) 1

SELLER

Janssen Biotech

Horsham, Pennsylvania, United States

website

Category Company
Founded 1979
Sector Life Science
DESCRIPTION

Janssen Biotech, Inc. is a biopharmaceutical company. Janssen Biotech was founded in 1979 and is based in Horsham, Pennsylvania.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Divestiture) 1 of 1
Country (United States) 1 of 1
Year (2018) 1 of 1
Size (of disclosed) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2018-05-02 BeneVir Biopharm

Gaithersburg, Maryland, United States

BeneVir Biopharm, Inc. is a biopharmaceutical company specializing in the development of oncolytic immunotherapies. BeneVir Biopharm is based in Gaithersburg, Maryland.

Buy -
Mergr

Product

Company

Legal